SCHEMBL10046492

SCHEMBL10046492

COc1cc(C2C3=C(CC(c4ccc(F)cc4)CC3=O)OC3=C2C(=O)CC(c2ccc(F)cc2)C3)ccc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTPN1 P18031 2/20 0.42
POLB P06746 1/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP1B1 Q16678 1/20 0.42
CYP19A1 P11511 1/20 0.41
CA2 P00918 2/20 0.41
NR3C1 P04150 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046482 0.90 GAA (0.51) GAAHTTALDH1A1LMNAMAPT
SCHEMBL10046494 0.89 GAA (0.56) GAAHTTALDH1A1LMNAMAPT
SCHEMBL14904060 0.83 GAA (0.51) GAAHTTALDH1A1LMNAMAPT
SCHEMBL10046493 0.80 GAA (0.47) GAAHTTALDH1A1LMNAMEN1
SCHEMBL325499 0.77 GPR174 (0.57) GAAHTTALDH1A1LMNAMAPT
SCHEMBL10046477 0.76 ALDH1A1 (0.46) GAAHTTALDH1A1MAPTMEN1
SCHEMBL10046487 0.75 GAA (0.73) GAAHTTALDH1A1LMNAMAPT
SCHEMBL10046491 0.72 TSHR (0.41) GAAHTTALDH1A1MAPTMEN1
SCHEMBL425310 0.70 CA2 (0.60) GAAMEN1KMT2AL3MBTL1PTPN1
SCHEMBL30545905 0.65 GPR174 (0.75) GAAHTTALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
WO-2012004390-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS ACOX3, CBR3, GALR3 GAA 1289/4885HTT 987/4885ALDH1A1 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.